Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01989754 · ClinicalTrials.gov registry record · Phase 4
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
A Phase 4 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 5,813
- Enrollment target
NCT01989754 is a Phase 4 study that has completed, run by Janssen Research & Development. The registered enrollment target is 5,813 participants.
The verdict
NCT01989754, a Phase 4 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5,813 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and at elevated risk of cardiovascular events.
Interventions
- DRUG Placebo
- DRUG Canagliflozin, 300 mg
- DRUG Canagliflozin, 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,813 participants |
| Start Date | 2014-01-16 |
| Est. Completion | 2017-02-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01989754
The ClinicalTrials.gov registry entry for NCT01989754 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 5,813 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01989754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01989754 about?
NCT01989754 is a clinical study titled "A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus". The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and at elevated risk of cardiovascular events.
What is the current status of trial NCT01989754?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5,813 participants. The study started on 2014-01-16. Estimated completion is 2017-02-23.
What interventions are being tested in trial NCT01989754?
The interventions under investigation include: Placebo (DRUG), Canagliflozin, 300 mg (DRUG), Canagliflozin, 100 mg (DRUG).
Who is sponsoring clinical trial NCT01989754?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.